

Ref. No.: QHTL/Sec/SE/2024-25/59

February 05, 2025

To,
The Manager,
Corporate Services,
BSE Limited,
14th floor, P J Towers, Dalal Street,
Mumbai – 400 001
Ref: Security ID: QUICKHEAL
Security Code: 539678

To,
The Manager,
Corporate Services,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Symbol: QUICKHEAL
Series: EQ

Subject: Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

Dear Sir / Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

The aforesaid information is also available on the website of the Company www.quickheal.co.in

For Quick Heal Technologies Limited

Vikram Dhanani
Compliance Officer

QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

(₹ in Crores, except earning per share)

Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2024 (Unaudited)	September 30, 2024 (Unaudited)	December 31, 2023 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited)	March 31, 2024 (Audited)
1	Income						
	Revenue from contract with customers	70.61	73.49	81.92	214.39	211.72	291.75
	Other income	4.91	5.20	4.15	15.17	14.57	21.39
	Total income	75.52	78.69	86.07	229.56	226.29	313.14
2	Expenses						
	Cost of material consumed	1.68	2.01	-	5.06	0.41	0.41
	Purchase of security software products	-	0.45	0.83	0.45	3.74	5.13
	(Increase) / decrease in security software products	-	-	1.20	-	0.96	1.29
	Employee benefit expenses	45.16	47.36	43.82	136.83	124.85	169.03
	Finance cost	0.06	0.05	-	0.16	-	0.13
	Depreciation and amortisation expenses	3.39	3.15	3.24	9.33	9.42	12.60
	Other expenses	27.54	20.60	24.45	70.16	74.25	98.34
	Total expenses	77.83	73.62	73.54	221.99	213.63	286.93
3	Profit/(loss) before tax (1-2)	(2.31)	5.07	12.53	7.57	12.66	26.21
4	Tax expense						
	Current tax						
	Pertaining to profit for the period	(0.38)	1.01	2.66	1.66	2.97	5.78
	Adjustments of tax relating to earlier periods (Net)	0.44	-	-	0.44	-	0.07
	Deferred tax	(2.48)	(0.09)	(0.19)	(2.82)	(0.51)	(3.88)
	Total tax expense	(2.42)	0.92	2.47	(0.72)	2.46	1.97
5	Profit/(loss) for the period (3-4)	0.11	4.15	10.06	8.29	10.20	24.24
6	Other comprehensive income/(loss) (net of tax)						
	Items that will not be reclassified subsequently to profit or loss :						
	Re-measurement of defined benefit plans	0.17	(0.51)	(0.71)	(0.13)	(0.32)	(0.16)
	Net (loss) or gain on FVOCI assets (refer note 2)	-	-	-	-	(12.55)	(13.45)
	Items that will be reclassified subsequently to profit or loss :						
	Exchange differences on translation of foreign operations	0.03	0.01	0.02	0.07	(0.04)	(0.06)
	Total other comprehensive income/(loss)	0.20	(0.50)	(0.69)	(0.06)	(12.91)	(13.67)
7	Total comprehensive income/(loss) (after tax) (5+6)	0.31	3.65	9.37	8.23	(2.71)	10.57
8	Paid-up equity share capital (face value of ₹10 each)	53.92	53.80	53.32	53.92	53.32	53.51
9	Other equity excluding revaluation reserves as per balance sheet	-	-	-	-	-	383.49
10	Earnings per share of ₹10 each: (not annualised except for the year ended March)						
	a) Basic	0.02	0.77	1.89	1.54	1.92	4.56
	b) Diluted	0.02	0.75	1.86	1.51	1.90	4.48

28



QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014


CIN: L72200MH1995PLC091408

NOTES TO THE STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

Notes to financial results:

- 1 The unaudited consolidated financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The above financial results for the quarter and nine months ended December 31, 2024 have been subjected to limited review by the statutory auditors of the Holding Company and reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at the meeting held on February 4, 2025.
- 2 During the year ended March 31, 2024 considering the financial position, liquidity condition, market conditions and geopolitical scenario in Israel, management based on its assessment had recorded a fair value loss in other comprehensive income (FVOCI) amounting to ₹ 12.55. Accordingly, the carrying value of investment made in L7 Defense Limited has been considered as ₹ Nil as at March 31, 2024.
- 3 As at December 31, 2024, the Holding Company has the following subsidiaries :
 - a) Quick Heal Technologies America Inc.
 - b) Seqrite Technologies DMCC.
- 4 The Group is engaged in providing cyber security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. consumer, enterprise and government. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Group has structured its operations into one operating segment viz. cyber security platform and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 5 The Board of Directors have proposed reappointment of following directors subject to approval from the Shareholders.
 - a) Mr. Kailash Katkar re-appointed as Chairman & Managing Director of the Holding Company w.e.f. April 1, 2025.
 - b) Mr. Sanjay Katkar re-appointed as Joint Managing Director of the Holding Company w.e.f. April 1, 2025.
- 6 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune
Date: February 4, 2025



For and on behalf of the Board of Directors

Kailash Katkar
Chairman & Managing Director
DIN No: 00397191

INTEGRATED FILING
A. Quarterly Financial Results

QUICK HEAL TECHNOLOGIES LIMITED Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014 CIN: L72200MH1995PLC091408							
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024 (₹ in Crores, except earning per share)							
Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2024 (Unaudited)	September 30, 2024 (Unaudited)	December 31, 2023 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited)	March 31, 2024 (Audited)
1	Income						
	Revenue from contract with customers	70.54	73.57	81.92	214.40	211.72	291.75
	Other income	4.91	5.21	4.14	15.18	14.55	21.37
	Total income	75.45	78.78	86.06	229.58	226.27	313.12
2	Expenses						
	Cost of material consumed	1.60	2.09	-	5.05	0.41	0.41
	Purchase of security software products	-	0.45	0.84	0.45	3.74	5.13
	(Increase) / decrease in security software products	-	-	1.20	-	0.96	1.29
	Employee benefit expenses	45.02	47.21	43.82	136.40	124.85	168.94
	Finance cost	0.06	0.05	-	0.16	-	0.13
	Depreciation and amortisation expenses	3.39	3.15	3.24	9.33	9.42	12.60
	Other expenses	27.58	20.94	24.47	70.66	74.39	98.58
	Total expenses	77.65	73.89	73.57	222.05	213.77	287.08
3	Profit/(loss) before tax (1-2)	(2.20)	4.89	12.49	7.53	12.50	26.04
4	Tax expense						
	Current tax						
	Pertaining to profit for the period	(0.38)	1.01	2.66	1.66	2.97	5.78
	Adjustments of tax relating to earlier periods (Net)	0.44	-	-	0.44	-	0.07
	Deferred tax	(2.48)	(0.09)	(0.19)	(2.82)	(0.51)	(3.88)
	Total tax expense	(2.42)	0.92	2.47	(0.72)	2.46	1.97
5	Profit/(loss) for the period (3-4)	0.22	3.97	10.02	8.25	10.04	24.07
6	Other comprehensive income/(loss) (net of tax)						
	Items that will not be reclassified subsequently to profit or loss :						
	Re-measurement of defined benefit plans	0.17	(0.51)	(0.71)	(0.13)	(0.32)	(0.16)
	Net (loss) or gain on FVOCI assets (refer note 2)	-	-	-	-	(12.55)	(13.45)
	Total other comprehensive income/(loss)	0.17	(0.51)	(0.71)	(0.13)	(12.87)	(13.61)
7	Total comprehensive income/(loss) (after tax) (5+6)	0.39	3.46	9.31	8.12	(2.83)	10.46
8	Paid-up equity share capital (face value of ₹ 10 each)	53.92	53.80	53.32	53.92	53.32	53.51
9	Other equity excluding revaluation reserves as per balance sheet	-	-	-	-	-	383.39
10	Earnings per share of ₹ 10 each: (not annualised except for the year ended March)						
	a) Basic	0.04	0.74	1.88	1.54	1.89	4.52
	b) Diluted	0.04	0.72	1.85	1.50	1.87	4.45



QUICK HEAL TECHNOLOGIES LIMITED

Regd. Office: Solitaire Business Hub, Office No. 7010 C & D, 7th Floor, Opposite Neco Garden Society, Viman Nagar, Pune - 411014

CIN: L72200MH1995PLC091408


NOTES TO THE STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS OF QUICK HEAL TECHNOLOGIES LIMITED FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

Notes to financial results:

- 1 The unaudited standalone financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The above financial results for the quarter and nine months ended December 31, 2024 have been subjected to limited review by the statutory auditors of the Company and reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on February 4, 2025.
- 2 During the year ended March 31, 2024 considering the financial position, liquidity condition, market conditions and geopolitical scenario in Israel, management based on its assessment had recorded a fair value loss in other comprehensive income (FVOCI) amounting to ₹ 12.55. Accordingly, the carrying value of investment made in L7 Defense Limited has been considered as ₹ Nil as at March 31, 2024.
- 3 The Company is engaged in providing cyber security software solutions. The Chief Operating Decision Maker (CODM) reviews the information pertaining to revenue of each of the target customer group (segments) viz. consumer, enterprise and government. However, based on similarity of activities/products, risk and reward structure, organisation structure and internal reporting systems, the Company has structured its operations into one operating segment viz. cyber security platform and as such there is no separate reportable operating segment as defined by Ind AS 108 "Operating segments".
- 4 The Board of Directors have proposed reappointment of following directors subject to approval from the Shareholders.
 - a) Mr. Kailash Katkar re-appointed as Chairman & Managing Director of the Company w.e.f. April 1, 2025.
 - b) Mr. Sanjay Katkar re-appointed as Joint Managing Director of the Company w.e.f. April 1, 2025
- 5 Previous period's figures have been regrouped / reclassified wherever necessary to make them comparable with the current period's classification / disclosure.

Place: Pune

Date: February 4, 2025.



For and on behalf of the Board of Directors

Kailash Katkar
Chairman & Managing Director

DIN No: 00397191

Independent Auditor's Review Report on consolidated unaudited financial results of Quick Heal Technologies Limited for the quarter and year to date December 31, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Quick Heal Technologies Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Quick Heal Technologies Limited (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended December 31, 2024 and the year to date results for the period from April 01, 2024 to December 31, 2024 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No.	Name of the Entity	Relationship with the Holding Company
1	Quick Heal Technologies America Inc.	Wholly owned subsidiary
2	Seqrite Technologies DMCC	Wholly owned subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MSKA & Associates

Chartered Accountants

6. The Statement includes the interim financial information of two subsidiaries which are not subject to review, whose interim financial information reflects total revenue of Rs. 1.34 crores and Rs. 4.33 crores, total net profit/(loss) after tax of Rs. (0.09) crores and Rs. 0.08 crores and total comprehensive income of Rs. (0.09) crores and Rs. 0.08 crores for the quarter ended December 31, 2024 and for the period from April 01, 2024 to December 31, 2024 as considered in the Statement. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

SD Khivasara
Shraddha D Khivasara
Partner

Membership No.: 134285

UDIN: *25134285BMNTCQ1620*



Place: Pune

Date: February 04, 2025

Independent Auditor's Review Report on standalone unaudited financial results of Quick Heal Technologies Limited for the quarter and year to date December 31, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Quick Heal Technologies Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Quick Heal Technologies Limited (hereinafter referred to as 'the Company') for the quarter ended December 31, 2024 and the year to date results for the period from April 01, 2024 to December 31, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

SD Khivasara
Shraddha D Khivasara
Partner

Membership No.: 134285

UDIN: **25134285BMNTCP6177**



Place: Pune

Date: February 04, 2025

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

– NOT APPLICABLE

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

S. No.	Particulars	in INR crore
1.	Loans / revolving facilities like cash credit from banks / financial institutions	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
2.	Unlisted debt securities i.e. NCDs and NCRPS	
A	Total amount outstanding as on date	
B	Of the total amount outstanding, amount of default as on date	0
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	0

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – NIL.

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) – NIL.